Medi-Weightloss is a physician-supervised medical weight-loss franchise: clinics that combine medical assessments and lab work, prescription medication, injections and supplements, and ongoing coaching visits. It is an established system of about a hundred clinics, and it converts capital into revenue better than any other brand in our data so far. It also charges one of the highest royalty rates.

What it costs

Total initial investment

$257,750–$490,860

Initial franchise fee

$60,000

Royalty

10% of gross sales, minimum $2,250 per month

System branding fee

1% of gross sales (or $250 per month)

Other recurring charges

Marketing automation $100–$500 per month; malpractice insurance about $4,300 a year

The investment range is the franchisor's own, quoted from its current FDD. A clinic is a modest office build, which is why the capital requirement is low for a medical concept. The franchisor looks for $100,000 of liquid capital and $400,000 net worth from an owner-operator, rising to $250,000 and $750,000 for a semi-absentee owner. Physicians are not required to own; the franchisor says business leaders with multi-unit experience also fit.

What clinics earn

Reporting clinics

57 of 82 open all year

Average gross sales

$989,143

Median gross sales

$883,593

Average gross profit

$794,551 (about 80.3%)

Average net income before other expenses

$231,299 (about 23.4%)

The sample is the 57 franchised clinics, out of 82 that operated all of 2024, that reported to the franchisor, so about 30% are missing. The median sits about 11% below the average.

This is one of the few Item 19s that goes past revenue. Gross profit of $794,551 means cost of goods, mainly medication, injections, supplements and lab costs, takes about 19.7% of sales. And the net income line, $231,299, is the closest thing to profit most weight-loss franchise buyers will see in a disclosure. Ask exactly which "other expenses" it excludes, and whether it is calculated before or after royalties: those two answers decide how close it is to what an owner takes home.

The ratio that matters

Against a midpoint investment of about $374,305, average gross sales of $989,143 give a revenue-to-investment ratio of roughly 2.64x, well above Hand & Stone at 1.92x and Spavia at 1.67x in our comparison. A small build that produces close to $1 million a year is the core of the case for this brand.

The royalty is the price of that ratio

A 10% royalty is high by the standard of our comparison, where most brands charge 5% to 8%. At average sales, the royalty and branding fee come to about $108,800 a year, roughly 11% of sales. Measured against gross profit, it is about 13.7%, because the clinic's product costs come out before it keeps anything.

Set that $108,800 against the $231,299 of net income before other expenses that Item 19 reports and the franchisor's share is large either way. The $2,250 monthly minimum royalty only binds below $270,000 of annual sales, so it matters mainly for a slow ramp.

GLP-1s changed the market after these figures

The disclosed results cover 2024, when compounded semaglutide was widely available under the FDA's drug-shortage rules. The FDA declared the shortage over in February 2025, and its allowance for compounding ended in April 2025 for state-licensed pharmacies and May 2025 for outsourcing facilities (FDA). Any weight-loss clinic that relied on compounded GLP-1s now faces different drug costs, pricing and patient demand. Ask the franchisor how 2025 revenue mix and cost of goods compare with 2024.

A mature, steady system

Franchised clinics went from 72 at the end of 2022 to 87 at the end of 2024, with 17 company-owned clinics: about 104 locations in total. That is slow, steady growth for a brand founded well before the GLP-1 boom, and a long operating history to draw on in validation calls.

Who this fits

Medi-Weightloss suits an operator who wants a compact medical clinic with strong revenue per dollar invested, is prepared to hire and manage licensed medical staff, and accepts a high royalty as the cost of a proven system. The semi-absentee path suits multi-unit investors with a strong clinic manager.

It fits poorly for a buyer who wants a light fee load, and for anyone unwilling to manage the regulatory and pricing risk that now surrounds prescription weight-loss drugs.

Before you sign

Ask for 2025 results and the revenue split between visits, medication and products. Find out what "net income before other expenses" excludes, and whether the 25 non-reporting clinics differ from the 57 that reported. Ask how clinics source GLP-1 medication now and what that does to margin. Then model the clinic at the median, after a 10% royalty, in the royalty calculator, and work through Item 19 and the due diligence checklist. Our medical wellness cost comparison sets it against the other clinic brands. For the clinic's back office, our clinical operations directory compares EHRs, lab accounts, medical supply distributors and hormone therapy programs.

Sources

Frequently asked questions

How much does a Medi-Weightloss franchise cost?
The franchisor quotes a total initial investment of $257,750 to $490,860 for a single clinic, citing Item 7 of its current FDD, including a $60,000 initial franchise fee. It asks for $100,000 liquid capital and $400,000 net worth for an owner-operator, and $250,000 and $750,000 for a semi-absentee owner.
How much does a Medi-Weightloss clinic make?
The 2025 FDD reports average gross sales of $989,143 and a median of $883,593 for 57 of the 82 franchised clinics that operated all of 2024. Average gross profit was $794,551 and average net income before other expenses was $231,299.
What are Medi-Weightloss's ongoing fees?
A royalty of 10% of gross sales with a $2,250 monthly minimum, and a system branding fee of 1% of gross sales (or $250 a month). At the reported average, that is about $108,800 a year, roughly 11% of sales and 13.7% of gross profit.
Does Medi-Weightloss prescribe GLP-1 drugs?
Medi-Weightloss runs physician-supervised weight-loss programs that include prescription medication. The FDA ended its shortage-era allowance for compounded semaglutide in 2025, which changed the cost and pricing of GLP-1 programs across the industry. The disclosed figures cover 2024, so ask the franchisor how the revenue mix and cost of goods have moved since.

Related guides

Get an alert when Medi-Weightloss's numbers change

Franchisors refile their FDD every year, and the figures move. We'll email you when this review is updated with Medi-Weightloss's new disclosure, plus occasional buyer-side insights. No spam.

Prefer downloads? Browse free resources.